Olaratumab – liečba pre pacientov s pokročilým sarkómom mäkkých tkanív nevhodných na chirurgickú liečbu alebo rádioterapiu // SOLEN

Onkológia 3/2018

Olaratumab – liečba pre pacientov s pokročilým sarkómom mäkkých tkanív nevhodných na chirurgickú liečbu alebo rádioterapiu

Olaratumab – treatment in patients with locally advanced soft tissue sarcoma unsuitable for surgery or radiotherapy Soft tissue sarcomas represent rare and histologically heterogeneous malignancy which has a very poor prognosis. Anthracyclines are the gold standard in treatment of advanced soft tissue sarcomas until recently. Monoclonal antibody olaratumab combined with cytotoxic drug doxorubicin has shown historical survival benefit in terms of significant prolongation of overall survival by nearly one year compared to standard treatment represented doxorubicin.

Keywords: treatment of soft tissue sarcomas, olaratumab